Products with Anti-Atherosclerotic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1250 | Diosgenin glucoside |
| Diosgenin glucoside and other synthetic glycosides with similar activities may be of use in the management of hypercholesterolemia and atherosclerosis. | |
| BCN1818 | Trichosanatine |
| 1. Trichosanatine and squamosamide, as potential candidates as lead compounds for further study in drug development process with the PP2A- α protein. 2. Trichosanatine can alleviate oxidized low-density lipoprotein induced endothelial cells injury via inhibiting the LOX-1/p38 MAPK pathway. | |
| BCN2207 | Ascorbic acid |
| Ascorbic acid (Vitamin C) is a water-soluble vitamin indicated for the prevention and treatment of scurvy, it has a protective effect on alloxan-induced damage by maintaining the activity of cellular antioxidants, it also protects sperm from endogenous oxidative DNA damage that could affect sperm quality and increases risk of genetic defects, particularly in populations with low ascorbic acid such as smokers.Ascorbic acid can reverse endothelial vasomotor dysfunction in the brachial circulation of patients with coronary artery disease. | |
| BCN2322 | Corilagin |
| Corilagin has antitumour, anti-inflammatory, antioxidant, antifibrotics, antiviral, antibacterial, hepatoprotective, antiatherogenic, and antihypertensive activities. Corilagin reduces the cytotoxicity induced by EV71 or CA16 on Vero cells with and IC50 value of 5.6 and 32.33 μg/mL, respectively; it shows the potential to protect against HSV-1-induced encephalitis, and the beneficial effects may be mediated by inhibiting TLR2 signaling pathways. Corilagin attenuates bleomycin-induced epithelial injury and fibrosis via inactivation of oxidative stress, proinflammatory cytokine release and NF-κB and TGF-β1 signaling; it suppresses the activity of beta-lactamase to some extent. | |
| BCN2336 | Eupatilin |
| Eupatilin has anti-inflammatory, and anti-tumor properties, it inhibits the MKN-1 gastric cancer cell proliferation via activation of caspase-3 and the metastatic potential of gastric cancer cells via down-regulation of NF-κB activity followed by reduction of pro-inflammatory cytokine-mediated MMPs expressions. Eupatilin inhibits the signalling of MAPK, IKK, NF-κB and eotaxin-1 in bronchial epithelial cells, leading to inhibition of eosinophil migration. Eupatilin is also a promising therapeutic agent against acute ischemia-induced renal damage, it significantly increases the levels of heat shock protein 70 and B-cell lymphoma protein, and it attenuates inducible nitric oxide synthase, Bcl-2-associated X protein, and caspase-3 levels. | |
